← Back to Search

Cannabinoid

THC for Stress (ETS Trial)

Phase < 1
Recruiting
Led By Harriet de Wit
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age between 18-35 years old
Be between 18 and 65 years old
Must not have
Daily use of medications outside of contraception
History of psychosis or mania
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (5 minutes before memory task) and 20 seconds after each cue presentation during the task

Summary

This trial aims to investigate how THC, a component of cannabinoids, affects how we remember stressful experiences. The researchers believe that THC can reduce our reactions to negative and fearful memories.

Who is the study for?
This trial is for individuals who are interested in how certain drugs might affect stress memories. Specific eligibility criteria details were not provided, so it's unclear who exactly can participate.
What is being tested?
The study is testing the effects of two doses of THC (5mg and 10mg) compared to a placebo on how people respond to stressful memories. Researchers think that THC might help reduce these stress responses.
What are the potential side effects?
While specific side effects aren't listed, common ones from THC may include dizziness, dry mouth, altered senses or mood changes. The exact experiences will vary by individual.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 35 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I take daily medication other than for birth control.
Select...
I have a history of psychosis or mania.
Select...
I am pregnant or trying to become pregnant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (5 minutes before memory task) and 20 seconds after each cue presentation during the task
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (5 minutes before memory task) and 20 seconds after each cue presentation during the task for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in emotional responses after stress memory cues compared to control cues after delta-9-tetrahydrocannabinol (THC) (5 mg, 10 mg) vs. placebo
Change in physiological responses after stress memory cue presentation compared to control cues
Secondary study objectives
Change in emotional responses one week later during non-drug retrieval session
Change in negative facial emotion expressions during cue presentation after THC (5 and 10 mg) vs placebo

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 5 mg delta-9-tetrahydrocannabinol (THC)Experimental Treatment1 Intervention
Marinol (dronabinol)
Group II: 10 mg delta-9-tetrahydrocannabinol (THC)Experimental Treatment1 Intervention
Marinol (dronabinol)
Group III: placeboPlacebo Group1 Intervention
Dextrose capsules

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor
1,053 Previous Clinical Trials
759,026 Total Patients Enrolled
Harriet de WitPrincipal InvestigatorUniversity of Chicago
7 Previous Clinical Trials
333 Total Patients Enrolled
~32 spots leftby Jul 2026